At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
Botulinum toxin type A +2 morebiological
Likely dose
Botulinum toxin type A 300 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomised, Double-blind, Parallel-group, Single-centre Comparative Study to Evaluate the Pharmacodynamic Profile of Dysport®, Botox®, and Xeomin® in the Extensor Digitorum Brevis (EDB) Model in Healthy Adult Male Participants
In Brief
A Phase 1 clinical trial evaluating Botulinum toxin type A for Healthy Participants. Completed, enrolled 45 participants across 1 site.
Detailed Summary
Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartJul 2021
First PostedJul 2021
Primary CompletionMar 2022
Study CompletionJun 2022
TodayJul 2026
First PostedJul 21, 2021
Enrollment StartJul 6, 2021
Primary CompletionMar 16, 2022
Study CompletionJun 8, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.9 years ago
Interventions
Botulinum toxin type Abiological
Intramuscular Injection, concentration 300 units (U)
Botulinum toxin type Abiological
Intramuscular Injection, concentration 50 U
Botulinum toxin type Abiological
Intramuscular Injection, concentration 50 U